USE OF CRRNA-MEDIATED CRISPR/CAS13A GENE EDITING SYSTEM IN TUMOR CELLS

WIPO Patent Application WO/2019/219024

A1

Provided is use of a crRNA-mediated CRISPR/Cas13a gene editing system in inhibiting and killing tumor cells. Cas13a protein, in U87 glioma cell line, can be mediated by a single-stranded crRNA onto a complementary RNA of interest and perform cleavage. Meanwhile, the Cas13a protein can also trigger the effect of associated cleavage in eukaryotic cells, that is, after starting to cleave the first RNA of interest, the Cas13a protein performs a random, non-targeted cleavage on other encountered RNA, thereby achieving effects of inhibiting and killing tumors such as reducing tumor cell index, and inhibiting the tumor formation rate and tumor size of mice.

WO/2003/054160	CELL LINES WITH LATENT IMMUNODEFICIENCY VIRUS AND METHODS OF USE THEREOF
WO/2022/164942	PNMA2-BASED CAPSIDS AND USES THEREOF
WO/2007/128338	PROCESS FOR CHROMOSOMAL ENGINEERING USING A NOVEL DNA REPAIR SYSTEM

KANG CHUNSHENG (CN)
WANG QIXUE (CN)
ZHOU JUNHU (CN)

PCT/CN2019/087019

November 21, 2019

May 15, 2019

Click for automatic bibliography generation  

KANG CHUNSHENG (CN)

C12N15/90; C12N15/113

WO2017219027A1

2017-12-21

CN108546718A	2018-09-18
CN107557455A	2018-01-09

OMAR 0. ABUDAYYEH: "C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector", SCIENCE, vol. 353, 2 June 2016 (2016-06-02), pages 6299, XP055407082, ISSN: 1095-9203
H. ZHU, ET AL.: "CRISPR-RT: a web application for designing CRISPR-C2c2 crR- NA with improved target specificity", BIOINFORMATICS, 14 September 2017 (2017-09-14), XP055658927, ISSN: 1367-4811

J.Z.M.C. PATENT AND TRADEMARK LAW OFFICE (GENERAL PARTNERSHIP) (CN)

View/Download PDF      PDF Help

Previous Patent: METHODS AND APPARATUS FOR CELL RE-SELECTION IN NEW RADIO SYSTEM

Next Patent: HAIR-CUTTING SHEARS